Mabgeek Biotechnology key facts
as of Oct 2026- Developer of a new antibody biotechnology designed to overcome autoimmune diseases.
- Mabgeek Biotechnology is valued at approximately $367.8M as of Oct 2026 (last reported valuation).
- It has raised $96.3M; the latest was IPO in Jul 2025.
- Notable investors include Shandong Finance Group, Shanghai Zhangjiang Science & Technology Venture Capital, DPH Capital, GF Qianhe, Optics Valley Financial Holdings Group — 16 tracked in total.
- Status: In IPO Registration.
Mabgeek Biotechnology's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Mabgeek Biotechnology: the Monday email on marks, rounds and moves
Mabgeek Biotechnology funding rounds
No funding rounds for Mabgeek Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Mabgeek Biotechnology
16+Membership and data by Private Market View
Mabgeek Biotechnology valuation
Mabgeek Biotechnology's last reported valuation was $368 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Mabgeek Biotechnology investors
16 investors are on record for Mabgeek Biotechnology, including Shandong Finance Group, Shanghai Zhangjiang Science & Technology Venture Capital, DPH Capital and GF Qianhe.
About Mabgeek Biotechnology
Developer of a new antibody biotechnology designed to overcome autoimmune diseases. The company focuses on research and development of antibody drugs for allergic inflammatory diseases and autoimmune diseases, enabling patients to receive effective treatment and improve their health conditions.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2016
- Employees
- 43
- Website
- mabgeek.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.